“Skin Clearance and Itch Relief in Black or African American Patients with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib: 140-Week Outcomes from Integrated Phase 3 Measure Up 1 and 2 Studies”, J of Skin, vol. 9, no. 6, p. s615, Nov. 2025, doi: 10.25251/9qs79351.